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Abstract 
 
Background 
To estimate the diagnostic accuracy of the VitalScan magnetocardiograph (MCG) for suspected acute 
coronary syndrome (ACS). 
 
Methods 
We undertook a prospective cohort study evaluating the diagnostic accuracy of the MCG in adults 
with suspected ACS. The reference standard of ACS was determined by an independent adjudication 
committee based on 30-day investigations and events. The cohort was split into a training sample, to 
derive the MCG algorithm and an algorithm combining MCG with a modified Manchester Acute 
Coronary Syndrome (MACS) clinical probability score, and a validation sample, to estimate diagnostic 
accuracy. 
 
Results 
We recruited 756 participants and analysed data from 680 (293 training, 387 validation), of whom 96 
(14%) had ACS. In the training sample the respective area under the receiving-operator 
characteristics (AUROC) curves were: MCG 0.66 (95% confidence interval (CI) 0.58 to 0.74), MACS 
0.64 (0.54 to 0.73) and MCG+MACS 0.70 (0.63 to 0.77). MCG specificity was 0.16 (0.12 to 0.21) at the 
threshold achieving acceptable sensitivity for rule out (>0.98). 
 
In the validation sample (N=387) the respective AUROCs were: MCG 0.56 (95% CI 0.48 to 0.64), 
MACS 0.69 (0.61 to 0.77) and MCG+MACS 0.64 (0.56 to 0.72). MCG sensitivity was 0.89 (95% CI 0.77 
to 0.95) and specificity 0.15 (0.12 to 0.20) at the rule-out threshold. MCG+MACS sensitivity was 0.85 
(95% CI 0.73 to 0.92) and specificity 0.30 (0.25 to 0.35).  
 
Conclusion 
The VitalScan MCG is currently unable to accurately rule out ACS and is not yet ready for use in 
clinical practice. Further developmental research is required. 
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Key messages 
 
What is already known about this subject? 
 Magnetocardiography (MCG) is a non-contact imaging technique that detects the magnetic 
fields generated by the electrical activity of the heart. 
 MCG can differentiate between patients with ischaemic heart disease and those without, 
and has potential to be used to rule out acute coronary syndrome (ACS). 
 
What does this study add? 
 This is the first clinical evaluation to be undertaken of the VitalScan MCG for ACS. It showed 
that the MCG is currently unable to accurately discriminate between people with and 
without ACS in a cohort with suspected ACS, and unable to accurately rule out ACS. 
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Introduction 
Chest pain accounts for around 6% of adult emergency department (ED) attendances.[1] The main 
reason for attendance and most common diagnostic assessment is for suspected acute coronary 
syndrome (ACS). Most people investigated for suspected ACS do not ultimately have a diagnosis of 
ACS, but investigation takes time and resources, and is an important contributor to ED crowding. 
 
Magnetocardiography (MCG) is a non-contact imaging technique that detects the magnetic fields 
generated by the electrical activity of the heart. The MCG technology has been evaluated in a 
number of clinical studies, demonstrating its potential usefulness in the detection of patients with 
stable angina and ACS including non-ST elevation myocardial infarction (NSTEMI).[2-11] These 
studies have not evaluated the use of MCG to rule-out of ACS in the ED, which requires the 
sensitivity and negative predictive value of the test to approach 100%. A portable MCG device could 
be used in the ED to assist with ACS rule-out, with potential savings of time and cost, and reductions 
in ED crowding. Specifically, early triage with the MCG could be used to identify patients with a very 
low risk of ACS who could be discharged without further investigation. 
 
A portable MCG device has been developed for cardiac magnetic field mapping, focused upon rapid 
chest pain assessment in the ED.[12] Evaluation of the device in 70 patients with ischaemic heart 
disease, 69 controls and 37 healthy volunteers showed that a logistic regression model based on 
MCG predictors could differentiate patients from controls with a specificity of 35.0%, sensitivity of 
95.4%, and negative predictive value of 97.8% (area under the curve 0.78).[13]  This suggested 
potential for the portable MCG to have a role in ruling out ACS, but further research was required to 
derive an algorithm for the MCG to diagnose ACS, determine the threshold used to indicate a 
positive test and then validate the algorithm and threshold in a separate cohort. The MCG measures 
a number of parameters that can be combined in an algorithm to predict the probability of ACS. This 
information is operationalised by setting a threshold above which further investigation is 
recommended and below which ACS can be considered to be ruled out. This threshold needs to be 
set to optimise sensitivity and thus allow safe ACS rule out. The algorithm and threshold then need 
to be validated in a separate cohort to determine the diagnostic accuracy for ACS. 
 
We aimed to: (1) Derive an algorithm and an appropriate rule-out threshold for the MCG; (2) 
Estimate the diagnostic accuracy of the MCG algorithm for ACS across its range of values and at the 
rule-out threshold; (3) Derive and estimate the diagnostic accuracy of an algorithm combining MCG 
parameters with a clinical probability score に the modified Manchester Acute Coronary Syndromes 
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(MACS) score;[14,15] (4) Estimate the diagnostic accuracy of the MCG in different risk strata, 
determined by the MACS score; and (5) Estimate the prognostic accuracy of the MCG for subsequent 
major adverse cardiac events (MACE). 
 
Methods 
We undertook a prospective, multi-centre cohort study comparing the VitalScan MCG (index test) to 
independent panel adjudication of ACS (reference standard) in patients presenting to the ED with 
chest pain symptoms suggestive of ACS. We collected data for training and validation samples, 
analysts from Creavo Technologies derived the algorithms and optimal threshold using the training 
sample, and we then independently estimated diagnostic accuracy of the algorithms using the 
validation sample. The authors were therefore responsible for study design, data collection, data 
analysis and interpretation of the findings, but played no role in developing the MCG algorithm. LU is 
an employee of Creavo Medical Technologies but played no role in developing the MCG algorithm. 
Tｴヴﾗ┌ｪｴﾗ┌デ デｴｷゲ ヮ;ヮWヴ さ┘Wざ ヴWaWヴゲ デﾗ デｴW ;┌デｴﾗヴゲ rather than anyone involved in developing the 
technology or the algorithm. 
 
We recruited adults (age 18 years or above) presenting to the EDs of five English hospitals with 
suspected ACS who were willing and able to provide written informed consent. We excluded people 
with atrial fibrillation, ST-segment Elevation MI (STEMI), a clear non-cardiac cause, 
haemodynamic instability (BP>220mmHg systolic, >110mmHg diastolic, <80mmHg systolic, 
<40mmHg diastolic, HR>160bpm), ventricular tachycardia or fibrillation, thoracic metal implants 
(including pacemaker or internal defibrillator), pregnancy or lactation, inability to lie down (i.e. 
supine position) or stay still on the examination bed, inability to understand the informed consent 
process and/or poor understanding of English, and inability to comply with the requirements of the 
protocol. 
 
The index test was the VitalScan MCG, which is shown in Figure 1. Participants underwent a resting 
MCG scan within 30 minutes (± 15 minutes) of the standard resting 12-lead ECG being completed in 
デｴW EDく Aﾉﾉ ゲI;ﾐゲ ┘WヴW ヮWヴaﾗヴﾏWS ;デ デｴW ヮ;デｷWﾐデげゲ HWSゲｷSW H┞ ; デヴ;ｷﾐWS ﾗヮWヴ;デﾗヴ ｷﾐ ;IIﾗヴS;ﾐIW ┘ｷデｴ 
デｴW M;ﾐ┌a;Iデ┌ヴWヴげゲ Iﾐゲデヴ┌Iデｷﾗﾐゲ aﾗヴ UゲW ﾏ;ﾐ┌;ﾉく RWゲ┌ﾉデゲ ┘WヴW ゲデﾗヴWS ;ﾐS デヴ;ﾐゲaWヴヴWS デﾗ デｴW ヴWゲW;ヴIｴ 
team, and were not revealed to the operator or any member of the clinical team. 
 
All participants underwent routine clinical assessment including resting 12-lead electrocardiograph 
(ECG) and one or more high sensitivity cardiac troponin measurement as per standard practice at the 
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hospital. The protocol did not specify any additional interventions other than the MCG. The modified 
MACS score, which includes several clinical variables taken from history and clinical examination but 
SﾗWゲﾐげデ デ;ﾆW ;IIﾗ┌ﾐデ ﾗa デヴﾗヮﾗﾐｷﾐが [Unpublished data, Body R, University of Manchester, July 2016] 
was calculated following all baseline procedures and each participant was assigned to a low (<7%), 
intermediate (7-25%) or high risk (>25%) subgroup for secondary analysis, based on producing 
meaningful numbers in each strata. We used a modified MACS score that excludes troponin to 
determine whether clinical and MCG assessment could allow ACS rule-out without troponin testing. 
Hospital electronic records were reviewed at 3 months and each participant was contacted by 
telephone, email or text message to identify any MACE (death, non-fatal acute myocardial infarction 
(AMI), emergency revascularisation, hospitalisation for myocardial ischaemia, life threatening 
arrhythmia). 
 
An independent adjudication committee consisting of two emergency physicians and one 
cardiologist determined whether or not each participant had a reference standard diagnosis of ACS 
by reviewing all available ED and in-patient medical records, including high sensitivity troponin 
results. A standardised definition for ACS was used that classified cases as: (1) AMI, based upon the 
third universal definition and divided into type 1 and type 2;[16] (2) Unstable angina, based upon 
clinical symptoms consistent with ACS but without criteria for AMI, taking into account results from 
functional or anatomical testing and/or subsequent MACE. The committee were blinded to MCG 
results. 
 
The sample size was determined on the basis of estimating diagnostic sensitivity for ACS with 
acceptable precision. We split the sample on the basis of date of recruitment across the whole 
sample to an early training sample and a later validation sample. For the training sample we 
estimated that, assuming ACS prevalence of 15%, 300 participants (45 with ACS) would provide a 
95% confidence interval (CI) ranging from 0.72 to 0.88 for an MCG algorithm with an AUROC of 0.8, 
or 0.84 to 0.96 for an AUROC of 0.9. For the validation sample, we estimated that, assuming ACS 
prevalence of 15%, 426 participants (64 with ACS) would provide a 95% CI ranging from 0.91 to 1.0 
for sensitivity of 0.98 and 0.35 to 0.45 for specificity of 0.4. 
 
Training sample: Analysts from Creavo Medical Technologies extracted the MCG parameters from 
the MCG data by applying signal processing algorithms to extract the MCG waveform for each 
channel (sensor), selecting intervals on the MCG waveform from which the MCG parameters were 
calculated, and applying algorithms to determine the MCG parameters. All MCG parameters that 
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could be potentially used for predictors of diagnostic status (ACS & non-ACS) were identified and the 
most pertinent parameters for predicting ACS determined. Methods used included, but were not 
limited to, dimensionality reduction, univariate and multivariate analysis. Using the pertinent 
predictors, a supervised classification model was fitted to the training dataset. Assessment of the 
training model was conducted using several key performance indicators including receiving-operator 
characteristic (ROC) analysis. An appropriate threshold for rule-out was selected by identifying the 
point on the ROC curve where sensitivity exceeded 98%. Another model was created using a 
combination of MCG parameters and clinical MACS score to estimate the probability of ACS. 
 
During derivation it was found that a number of scans were too complex for meaningful analysis and 
interpretation. These scans were automatically coded as MCG positive (i.e. ACS probability = 1). We 
felt this best reflected clinical practice, whereby an uninterpretable scan would require further 
investigation rather than allowing ACS rule-out. 
 
Validation sample: An independent statistician applied the MCG and MCG+MACS algorithms to the 
validation sample data to construct ROC curves, estimate the area under the ROC (AUROC) and 
estimate the sensitivity and specificity of each algorithm at the rule-out threshold. We also 
undertook stratified analysis of MCG sensitivity and specificity in low, moderate and high-risk 
groups. We estimated the prognostic accuracy of the MCG by calculating the relative risk of MACE 
with a positive MCG result compared to a negative result. 
 
All participants provided written informed consent. The protocol was approved by the Sheffield 
Research Ethics Committee (reference 16/YH/0454). The study was prospectively registered at 
ClinicalTrials.gov (NCT02921438), see https://clinicaltrials.gov/ct2/show/NCT02921438 .  
 
Patient and Public Involvement 
Development of the research question and outcome measures was informed by previous studies 
undertaken by the research team that involved patient representatives and evaluation of patient 
experience.[17,18] A patient representative on the Study Steering Committee (David Houghton) 
advised on the design and conduct of the study, and interpretation of results. Patients were not 
involved in the recruitment to and conduct of the study. We have no plans to disseminate the 
findings to study participants. 
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Results 
We recruited 756 eligible participants between 6 February 2017 and 30 April 2018 across five sites, 
of whom 746 completed the study. Figure 2 shows the flow of participants. We were unable to 
record a usable MCG scan for 52 (7%, 28 training, 24 validation) or adjudicate a reference standard 
for 16 (2%, 6 training, 10 validation), with 2 participants having neither MCG scan nor reference 
standard. This left 293 training and 387 validation cases in the analysis. The mean age of participants 
was 59 years (58 training, 59 validation) and mean MACS score was 19 (training 17, validation 21). 
Table 1 compares other characteristics. Participants in the validation sample had a higher prevalence 
of previous cardiac history, risk factors for coronary artery disease and high risk MACS score, but the 
prevalence of reference standard ACS was similar in the two samples (15% (43/293) v 14% (53/387)). 
 
Table 1: Baseline characteristics of participants included in the training and validation samples 
 
Training sample Validation sample Combined sample 
n % n % n % 
Female  111 38% 139 36% 250 37% 
Ethnicity Asian / Asian British 15 5% 30 8% 45 7% 
Black / African / Caribbean / 
Black British 
8 3% 7 2% 15 2% 
Declined to answer 0 0% 2 1% 2 0% 
Mixed multiple ethnic groups 3 1% 1 0% 4 1% 
Other ethnic group 1 0% 5 1% 6 1% 
White / Caucasian 266 91% 342 88% 608 89% 
Patient has previous cardiac 
history 
 98 33% 156 40% 254 37% 
Known family history of CAD 
and/or MI <60yrs old 
 119 41% 167 43% 286 42% 
Known dyslipidaemia  92 31% 177 46% 269 40% 
Known diabetes  38 13% 71 18% 109 16% 
Known hypertension  117 40% 185 48% 302 44% 
Current smoker (within 4 weeks) 48 16% 77 20% 125 18% 
Presence of acute ischaemia on ECG 10 3% 33 9% 43 6% 
Pre-test probability score 
(MACS) 
High risk (> 25%) 56 19% 105 27% 161 24% 
Intermediate risk (7-25%) 176 60% 210 54% 386 57% 
Low risk (< 7%) 60 20% 72 19% 132 19% 
Relevant patient diagnosis as 
recorded on the discharge 
summary 
Non-cardiac cause 177 60% 229 59% 406 60% 
NSTEMI 30 10% 40 10% 70 10% 
Other cardiac cause 71 24% 103 27% 174 26% 
Unstable angina (UA) 14 5% 15 4% 29 4% 
Reference standard positive for ACS 43 15% 53 14% 96 14% 
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ACS categorisation Type 1 MI 34 12% 42 11% 76 11% 
Type 2 MI 0 0% 2 1% 2 0% 
Unstable Angina 9 3% 9 2% 18 3% 
 
 
The training sample was used to derive an algorithm for the MCG and identify a threshold for 
positivity that provided acceptable sensitivity for rule-out, and derive an algorithm that combined 
the MCG and MACS score. A total of 293 participants in the training sample had both a valid MCG 
index test result and a reference standard diagnosis. One participant did not have a valid MACS 
score. The ROC curves for these algorithms and the MACS score are shown in Figure 3. The 
respective AUROCs were: MCG 0.66 (95% CI 0.58 to 0.74), MACS 0.64 (0.54 to 0.73) and MCG+MACS 
0.70 (0.63 to 0.77). The specificity of the MCG was 0.16 (0.12 to 0.21) at the rule-out threshold that 
achieved sensitivity of 0.98 (0.88 to 1.0). 
 
The validation sample was used to estimate diagnostic accuracy. 387 participants had both a valid 
MCG index test result and a reference standard diagnosis. Figure 4 shows the ROC curves for the 
MCG algorithm, MACS and MCG+MACS combined in the validation sample. The respective AUROCs 
were: MCG 0.56 (95% CI 0.48 to 0.64), MACS 0.69 (0.61 to 0.77) and MCG+MACS 0.64 (0.56 to 0.72). 
Table 2 shows the 2x2 table comparing the MCG algorithm to the ACS reference standard. Sensitivity 
was 0.89 (95% CI 0.77 to 0.95), specificity 0.15 (0.12 to 0.20), positive predictive value 0.14 (0.11 to 
0.18) and negative predictive value 0.89 (0.79 to 0.95). 
 
Table 2: Comparison of the MCG algorithm to the ACS reference standard in the validation sample 
using the derived rule-out threshold 
  Reference standard 
  ACS No ACS Totals 
MCG positive 47 283 330 
    
MCG negative 6 51 57 
    
Totals 53 334 387 
 
Table 3 shows the 2x2 table comparing the MCG+MACS algorithm to the ACS reference standard. 
Sensitivity was 0.85 (95% CI 0.73 to 0.92), specificity 0.30 (0.25 to 0.35), positive predictive value 
0.16 (0.12 to 0.21) and negative predictive value 0.93 (0.86 to 0.96). 
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Table 3: Comparison of the MCG+MACS algorithm to the ACS reference standard in the validation 
sample using the derived rule-out threshold 
  Reference standard 
  ACS No ACS Totals 
MCG+MACS positive 45 235 280 
    
MCG+MACS negative 8 99 107 
    
Totals 53 334 387 
 
 
We estimated the diagnostic accuracy of the MCG algorithm in the validation sample stratified by 
MACS score into low, moderate and high risk strata. Sensitivity and specificity were 0.50 (95% CI 
0.15 to 0.85) and 0.15 (0.08 to 0.25) respectively in the low risk strata, 0.90 (0.70 to 0.97) and 0.17 
(0.12 to 0.23) respectively in the moderate risk strata, and 0.93 (0.78 to 0.98) and 0.11 (0.06 to 0.20) 
in the high risk strata. 
 
There were only 4 MACE in the training sample and 11 MACE in the validation sample, providing very 
limited power to analyse prediction of MACE. Analysis showed that all relative risks had wide 
confidence intervals with no evidence that MCG results predicted MACE. There were no adverse 
device effects from performing the MCG scan. 
 
Discussion 
This study is the first clinical investigation of a new device, the VitalScan MCG, for ruling out ACS in 
patients presenting to the ED with suspected ACS. The training sample was used to derive an 
algorithm for predicting the probability of ACS and to derive an appropriate threshold for the 
algorithm to achieve high sensitivity for rule-out. The ROC analysis showed how the device 
performed, in terms of sensitivity and specificity, across the range of cut-offs for the predicted 
probabilities of ACS from the algorithm.  An AUROC exceeding 0.7 indicates a model that is good at 
discriminating between patients at high and low risk of ACS, and an AUROC exceeding 0.8 a strong 
model. Our findings indicate that the MCG only just achieved good discrimination when combined 
with modified MACS in the training sample. Estimates from the training sample should not be used 
to indicate how test will perform in practice because the algorithm will have been over-fitted to the 
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data. The validation sample provides a better estimate of performance in practice. The AUROC 
estimates from the validation sample indicated that MCG discrimination of ACS was not significantly 
better than chance. It is notable that the performance of MCG+MACS combined appeared to be 
worse than modified MACS alone in the validation sample. This is probably explained by 
classification of complex MCG scans as positive, which eliminates any potential discriminant value 
associated with modified MACS in such cases. 
 
Analysis of sensitivity and specificity at the optimal threshold for ruling out showed that the MCG 
algorithm achieved 98% sensitivity as intended in the training sample, but this was at the expense of 
specificity of 16%. Statistical shrinkage (which is when a fitted relationship appears to perform less 
well on a new dataset (the validation set) than on the data set used for fitting (the training dataset)) 
resulted in sensitivity falling to 89% in the validation sample, which is not acceptable for ACS rule-
out. This emphasises the importance of estimating diagnostic parameters in a validation cohort 
rather than relying on estimates from the data set in which the algorithm or threshold for positivity 
were derived. 
 
This study had a number of strengths that assist our confidence in the validity and generalisability of 
the findings. Separation of the training and validation samples was carefully maintained, and analysis 
of the validation sample was undertaken by a statistician (SJW) who was independent of the 
manufacturers and not involved in developing the technology or deriving the algorithm. Reference 
standard adjudication was undertaken by an independent adjudication committee, who were blind 
to the results of the index test. The results of the index test were also not available to treating 
clinicians, thus removing the potential for work-up bias (i.e. the index test results influencing 
ordering of the investigations used to determine the reference standard). The study was conducted 
across five sites, thus ensuring a wide spectrum of patients and enhancing generalisability. 
 
The study also had some limitations. Exclusion of patients with atrial fibrillation, inability to lie down 
and inability to speak English may have limited the generalisability of findings. Splitting the sample 
on the basis of time (with the training sample being recruited before the validation sample) may 
have resulted in systematic differences between the two samples, with the validation sample having 
a higher prevalence of previous cardiac history, risk factors for coronary artery disease and high risk 
modified MACS score. The study was designed to evaluate diagnostic accuracy for ACS rather than 
prognostic accuracy for MACE, and the sample size estimate was determined on this basis. As a 
consequence the study was under-powered to estimate prognostic accuracy for MACE. New 
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technologies could provide useful prognostic information without adding useful diagnostic 
information, but we are unable to determine this for the MCG in this study.  
 
We were not involved in development of the device or derivation of the algorithm, so we are unable 
to provide details of the methods used. An inevitable consequence of our independence is that we 
ｴ;S デﾗ デヴW;デ デｴW ;ﾉｪﾗヴｷデｴﾏ ;ゲ ; さHﾉ;Iﾆ Hﾗ┝ざ ;ﾐS ﾉｷﾏｷデ ﾗ┌ヴ ;ﾐ;ﾉ┞ゲｷゲ デﾗ SWデWヴﾏｷﾐｷﾐｪ Sｷ;ｪﾐﾗゲデｷI 
performance. We are therefore unable to provide insights as to why the device performed as it did 
or how performance could be improved. Communication with the analysts from Creavo 
Technologies suggests that operation of the device may have been suboptimal. Diagnostic 
parameters are obtained from both the ECG-like signal and from markers placed on the magneto-
cardiac image. Extracting these accurately is critical to the performance of the device. Therefore, 
positioning of the scan head so that the magneto-cardiac image lies in the centre of the field of view 
of the scan head is critical to the functioning of the device. Misalignment of the scan creates two 
problems. Firstly, magnetic signals can be missed, resulting in a lower (or even absent) signal 
strength and secondly, the field pattern becomes distorted. Both of these lead to inaccuracies in the 
parameters extracted. As there was no feedback given to the operators to allow re-positioning of 
scans, from the device or following analysis, there was no ability to improve the operation. This has 
been corrected in the next iteration of the device, and has been combined with improvements in the 
ergonomics and technology.  
 
In conclusion, this study was conducted to evaluate the real world performance of a first-generation 
bedside MCG device. We have shown that the VitalScan MCG cannot yet meet the high accuracy 
required to rule out ACS for use in clinical practice. Further developmental research is being 
undertaken to understand failure of the MCG to identify ACS and improve diagnostic performance 
within the next iteration of the device which will be evaluated in further clinical studies.  
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Figure1: The VitalScan Magnetocardiograph 
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Figure 2: Flow of participants through study 
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Figure 3: Receiver Operating Characteristic (ROC) Curves for MCG, MACS and 
MCG+MACS combined in the training sample 
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Figure 4: Receiver Operating Characteristic (ROC) Curves for MCG, MACS and 
MCG+MACS combined in the validation sample 
 
